Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.3.1.108 (
TAT
)
2,389
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
FcgammaRI requires both the intracellular domain of the alpha-chain and associated leukocyte Fc receptor (FcR) gamma-chains for its biological function. We recently found the C terminus of
periplakin
to selectively interact with the cytoplasmic domain of the FcgammaRI alpha-chain. It thereby enhances the capacity of FcgammaRI to bind, internalize, and present antigens on MHC class II. Here, we characterized the domains involved in FcgammaRI-
periplakin
interaction using truncated and alanine-substituted FcgammaRI mutants and randomly mutagenized
periplakin
. This allowed us to design
TAT
peptides that selectively interfered with endogenous FcgammaRI-
periplakin
interactions. The addition of these peptides to FcgammaRI-expressing cells modulated FcgammaRI ligand binding, as assessed by erythrocyte-antibody-rosetting. These data support a dominant-negative role of C-terminal
periplakin
for FcgammaRI biological activity and implicate
periplakin
as a novel regulator of FcgammaRI in immune cells.
...
PMID:Modulation of FcgammaRI (CD64) ligand binding by blocking peptides of periplakin. 1516 26
